Edition:
India

Arcturus Therapeutics Ltd (ARCT.OQ)

ARCT.OQ on NASDAQ Stock Exchange Global Market

9.15USD
19 Jan 2018
Change (% chg)

-- (--)
Prev Close
$9.15
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
28,452
52-wk High
$15.19
52-wk Low
$6.59

Latest Key Developments (Source: Significant Developments)

Bradley Thomas Sorenson Reports 5.6 Pct Stake In Arcturus Therapeutics As Of Nov. 16, 2017
Friday, 19 Jan 2018 

Jan 19 (Reuters) - Bradley Thomas Sorenson: :BRADLEY THOMAS SORENSON REPORTS 5.6 PERCENT STAKE IN ARCTURUS THERAPEUTICS LTD AS OF NOVEMBER 16, 2017 - SEC FILING.BRADLEY THOMAS SORENSON - PURCHASED ARCTURUS THERAPEUTICS' SHARES BASED ON BELIEF THAT SUCH SECURITIES, WHEN PURCHASED, WERE "UNDERVALUED".  Full Article

Arcturus Announces Expansion Of Collaboration With Takeda
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS ANNOUNCES EXPANSION OF COLLABORATION WITH TAKEDA PHARMACEUTICALS TO DEVELOP RNA-BASED THERAPEUTICS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) AND OTHER GI DISORDERS.ARCTURUS THERAPEUTICS - TAKEDA, CO TO DEVELOP RNA-BASED THERAPEUTICS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS, OTHER GASTROINTESTINAL.ARCTURUS - TO DEVELOP TREATMENT OF NASH AND GI RELATED DISORDERS USING CO'S LUNAR LIPID-MEDIATED DELIVERY SYSTEMS & UNA OLIGOMER CHEMISTRY.  Full Article

Arcturus and Curevac Enter Into Strategic Collaboration To Jointly Novel Messenger RNA Therapeutics
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Arcturus Therapeutics Ltd ::CO, CUREVAC AG ENTER INTO STRATEGIC COLLABORATION TO JOINTLY DISCOVER, DEVELOP,COMMERCIALIZE NOVEL MESSENGER RNA THERAPEUTICS.DEVELOPMENT COSTS WILL BE SHARED BETWEEN COS,WITH PLANS TO CO-COMMERCIALIZE PRODUCTS IN FUTURE UNDER PROFIT SHARING ARRANGEMENT.  Full Article

Arcturus Therapeutics Ltd Says Raised About $67.8 Million In Equity Financing
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS LTD SAYS RAISED ABOUT $67.8 MILLION IN EQUITY FINANCING .  Full Article

Alcobra qtrly ‍net loss per share $0.09​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Alcobra Ltd :Alcobra announces third quarter 2017 financial results and provides corporate update.Alcobra Ltd - qtrly ‍net loss per share $0.09​.  Full Article

ARCTURUS, SYNTHETIC GENOMICS ANNOUNCE ALLIANCE TO DEVELOP VACCINES, THERAPEUTICS
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Synthetic Genomics::ARCTURUS THERAPEUTICS AND SYNTHETIC GENOMICS ANNOUNCE STRATEGIC ALLIANCE TO DEVELOP NEXT-GENERATION VACCINES AND THERAPEUTICS.UNDER COLLABORATION, CO WILL HAVE EXCLUSIVE ACCESS TO LUNAR TECHNOLOGY FOR VACCINES AND THERAPEUTICS, USING SELF-AMPLIFYING RNA​.UNDER, COLLABORATION, ‍ARCTURUS WILL RECEIVE UPFRONT CASH PAYMENT, RESEARCH AND DEVELOPMENT SUPPORT, PRE-CLINICAL, DEVELOPMENT, SALES MILESTONE PAYMENTS.‍UNDER COLLABORATION, ARCTURUS WILL ALSO RECEIVE ROYALTY PAYMENTS ON ANY FUTURE SUBLICENSED PRODUCTS ​.  Full Article

Alcobr, Arcturus Therapeutics agree to merge
Thursday, 28 Sep 2017 

Sept 27 (Reuters) - Alcobra Ltd ::Alcobra ltd and Arcturus therapeutics, inc. Agree to merge.Proposed merger has been unanimously approved by boards of directors of both companies.Co, Arcturus therapeutics​ ‍sign definitive agreement to merge two companies in an all-stock transaction.Holders of arcturus outstanding capital stock immediately prior to merger will receive ordinary shares of alcobra in merger​.Conversion ratio for deal is based on a valuation of co of $46.7 million, including about $35 million of expected alcobra cash at closing​.Combined company well-capitalized with approximately $40 million in cash projected at closing.Joseph E. Payne is expected to serve as president and chief executive officer of combined company​.On pro forma basis for combined co,alcobra shareholders to own about 40%,arcturus shareholders expected to own about 60% of combined co.Board of directors of combined company will be comprised of seven members​.$40 million in cash projected at closing is expected to fund co through multiple value creation milestones and into early clinical development.Seven members will include three members to be designated by Alcobra and four members to be designated by Arcturus​.  Full Article

Alcobra reports Q4 loss per share $0.22
Wednesday, 15 Feb 2017 

Alcobra Ltd : Alcobra announces fourth-quarter and full-year 2016 financial results and provides corporate update . Qtrly loss per share $0.22 . Alcobra ltd - qtrly loss per share $0.22 .Q4 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.  Full Article

Alcobra reports Q2 loss per share of $0.21
Tuesday, 30 Aug 2016 

Alcobra Ltd : Alcobra announces second quarter 2016 financial results and provides corporate update .Qtrly loss per share $0.21.  Full Article

Alcobra grants European orphan drug designation for Metadoxine
Tuesday, 19 Jul 2016 

Alcobra Ltd : Alcobra granted European orphan drug designation for Metadoxine in fragile X syndrome .European commission has granted orphan drug designation to Metadoxine for treatment of fragile X syndrome within European Union.  Full Article

BRIEF-Bradley Thomas Sorenson Reports 5.6 Pct Stake In Arcturus Therapeutics As Of Nov. 16, 2017

* BRADLEY THOMAS SORENSON REPORTS 5.6 PERCENT STAKE IN ARCTURUS THERAPEUTICS LTD AS OF NOVEMBER 16, 2017 - SEC FILING